PTGX — Protagonist Therapeutics, Inc. stock price, charts and financials
QT79Protagonist Therapeutics, Inc.Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
132.28
-4.36-3.19%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -1.81 | Insider Own | 6.89% | Shs Outstand | 64.31M | Perf Week | 0.39% |
| Market Cap | 8.79B | Forward P/E | - | EPS next Y | -0.50 | Insider Trans | -7.21% | Shs Float | 52.49M | Perf Month | 9.16% |
| Enterprise Value | 8.60B | PEG | 0.21 | EPS next Q | - | Inst Own | - | Short Float | 15.80% | Perf Quarter | 38.06% |
| Income | -113.36M | P/S | 118.65 | EPS this Y | 333.53% | Inst Trans | - | Short Ratio | 11.56 | Perf Half Y | 71.38% |
| Sales | 74.06M | P/B | 13.57 | EPS next Y | -111.87% | ROA | -16.45% | Short Interest | 8.29M | Perf YTD | 56.45% |
| Book/sh | - | P/C | - | EPS next 5Y | 16.50% | ROE | -17.76% | 52W High | 138.72 -4.64% | Perf Year | 150.16% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -21.29% | 52W Low | 48.88 170.63% | Perf 3Y | 614.27% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 19.43% 9.67% | Gross Margin | 99.45% | Volatility | 4.12% 4.74% | Perf 5Y | 190.60% |
| Dividend TTM | - | EV/Sales | 116.17 | EPS Y/Y TTM | -142.79% | Oper. Margin | -192.36% | ATR (14) | 5.98 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.76 | Sales Y/Y TTM | -82.95% | Profit Margin | -154.88% | RSI (14) | 57.72 | Recom | 2.04 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.76 | EPS Q/Q | 126.32% | SMA20 | 0.79% | Beta | 1.74 | Target Price | 138.40 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 100.00% | SMA50 | 14.29% | Rel Volume | 0.79 | Prev Close | 136.64 |
| Employees | 132 | LT Debt/Eq | 0.01 | Earnings | Aug 05 | SMA200 | 40.42% | Avg Volume | 695.83K | Price | 132.28 |
| IPO Date | Aug 11, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 109.99% 381.69% | Net Debt/EBITDA | 1.61 | Volume | 548,760 | Change | -3.19% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-17-26 | Reiterated | Johnson Rice | $137 → $165 | |
| Jul-14-26 | Reiterated | Barclays | Overweight | $108 → $151 |
| Jul-07-26 | Reiterated | Truist Securities | Buy | $121 → $145 |
| May-06-26 | Reiterated | Goldman Sachs | Neutral | $97 → $110 |
| Mar-18-26 | Reiterated | Jefferies | Buy | $121 |
| Jan-30-26 | Reiterated | HC Wainwright & Co. | Buy | $50 → $117 |
| Jan-05-26 | Reiterated | Truist Securities | Buy | $88 → $110 |
| Dec-17-25 | Reiterated | Barclays | Overweight | $72 → $108 |
| Oct-28-25 | Reiterated | Truist Securities | Buy | $76 → $88 |
| Oct-13-25 | Reiterated | Johnson Rice | $72 → $112 |
Latest News
Jul-26-26
Jul-26-2603:57AM
Jul-25-26
Jul-25-2604:09AM
Jul-22-26
Jul-22-2608:20AM
Jul-16-26
03:53PM
Jul-14-26
Jul-14-2607:39AM
Jul-13-26
04:26AM
New Strong Buy Stocks for July 13thzacks.com
Jul-09-26
Jul-08-26
Jul-08-2611:30AM
Jul-07-26
07:37AM
Jul-01-26
Jun-29-26
Jun-29-2605:00PM
Jun-24-26
Company
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 74 | 46 | 434 | 60 | 27 | 27 | 29 | 0 | 31 | |
| Cost of Goods Sold Incl. D&A | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 74 | 45 | 434 | 60 | 27 | 27 | 29 | 0 | 31 | |
| Selling, General and Administrative Excl. Other | 46 | 45 | 43 | 33 | 32 | 27 | 19 | 16 | 14 | |
| Research and Development | 170 | 159 | 138 | 120 | 126 | 126 | 76 | 65 | 59 | |
| Other Operating Expense | 1 | -1 | 1 | 1 | 0 | 0 | -2 | 0 | 0 | |
| Operating Income | -142 | -158 | 253 | -94 | -131 | -126 | -65 | -81 | -42 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 27 | 29 | 27 | 15 | 4 | 0 | 0 | 3 | 3 | |
| Net Income Before Taxes | -116 | -129 | 279 | -79 | -127 | -126 | -65 | -78 | -40 | |
| Income Taxes | -1 | 1 | 4 | 0 | 0 | 0 | 1 | -1 | -1 | |
| Consolidated Net Income | -114 | -130 | 275 | -79 | -127 | -126 | -66 | -77 | -39 | |
| Net Income From Continuing Operations | -114 | -130 | 275 | -79 | -127 | -126 | -66 | -77 | -39 | |
| Net Income | -114 | -130 | 275 | -79 | -127 | -126 | -66 | -77 | -39 | |
| EPS (Recurring) | -1.80 | -2.05 | 4.47 | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | |
| EPS (Basic, Before Extraordinaries) | -1.80 | -2.05 | 4.47 | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | |
| EPS (Diluted) | -1.81 | -2.05 | 4.23 | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | |
| EBITDA | -113 | -128 | 280 | -76 | -124 | -123 | -64 | -77 | -39 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 9.13 | — | — | — | — | — | — | |
| Price To Sales Ratio | 116.19 | 121.52 | 5.51 | 21.78 | 19.80 | 58.27 | 23.64 | — | 4.78 | |
| Gross Margin | 100.00 | 97.83 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | — | 100.00 | |
| Operating Margin | -191.89 | -343.48 | 58.29 | -156.67 | -485.19 | -466.67 | -224.14 | — | -135.48 | |
| Net Margin | -154.05 | -282.61 | 63.36 | -131.67 | -470.37 | -466.67 | -227.59 | — | -125.81 | |
| Shares Outstanding | 65 | 64 | 62 | 57 | 49 | 46 | 34 | 26 | 22 | |
| Market Capitalization | 8,598 | 5,590 | 2,393 | 1,307 | 535 | 1,573 | 685 | 183 | 148 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Waddill William D. | Director | Jun 23 '26 | Option Exercise | 16.54 | 9,000 | 148,860 | 16,825 | Jun 25 |
| Waddill William D. | Director | Jun 23 '26 | Sale | 117.94 | 9,000 | 1,061,460 | 7,825 | Jun 25 |
| Waddill William D. | Director | Jun 10 '26 | Option Exercise | 14.96 | 9,000 | 134,640 | 16,825 | Jun 11 |
| Waddill William D. | Director | Jun 10 '26 | Sale | 107.68 | 9,000 | 969,120 | 7,825 | Jun 11 |
| Waddill William D. | Director | May 29 '26 | Sale | 99.64 | 9,000 | 896,760 | 7,825 | Jun 01 |
| Waddill William D. | Director | May 29 '26 | Option Exercise | 11.80 | 9,000 | 106,200 | 16,825 | Jun 01 |
| PATEL DINESH V PH D | President and CEO | May 12 '26 | Option Exercise | 21.58 | 75,000 | 1,618,500 | 598,478 | May 12 |
| PATEL DINESH V PH D | President and CEO | May 12 '26 | Sale | 100.12 | 75,000 | 7,509,000 | 523,478 | May 12 |
| Giraudo Bryan | Director | May 08 '26 | Sale | 100.00 | 11,130 | 1,113,000 | 0 | May 11 |
| Giraudo Bryan | Director | May 07 '26 | Option Exercise | 6.63 | 36,000 | 238,560 | 43,825 | May 11 |
| Giraudo Bryan | Director | May 07 '26 | Sale | 100.12 | 48,000 | 4,805,880 | 6,000 | May 11 |
| Ali Asif | Chief Financial Officer | Apr 20 '26 | Sale | 105.47 | 1,750 | 184,573 | 59,003 | Apr 21 |
| MOLINA ARTURO MD | Chief Medical Officer | Mar 26 '26 | Sale | 104.79 | 15,000 | 1,571,850 | 84,115 | Mar 27 |
| SELICK HAROLD E | Director | Mar 26 '26 | Option Exercise | 12.88 | 24,000 | 309,120 | 84,845 | Mar 27 |
| SELICK HAROLD E | Director | Mar 26 '26 | Sale | 105.00 | 24,000 | 2,520,000 | 60,845 | Mar 27 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.